Jones Hill Capital LP — 13F Holdings & Portfolio
CIK 2102314 · latest 13F-HR filed 2026-11-13
Jones Hill Capital LP manages $589.2M in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are BMRN (11.93%), BCRX (10.01%), TVTX (9.59%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 19 new positions and exited 15; 4 existing positions rose in reported value and 9 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-13
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 71.6%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated May 6, 2026.
EIGHTH FLOOR SOUTH
NEW YORK, NY 10013
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| GANDRUD, SOREN ALEXANDER, MAKRIYANNIS Control | CIO, LIMITED PARTNER since Apr 2025 | 75% or more | Individual |
| JHC MANAGER GP LLC Control | GENERAL PARTNER since Apr 2025 | Less than 5% | Domestic Entity |
| MEEKINS, CHRISTOPHER, MARTIN Control | CCO, COO. GC, PARTNER since Apr 2025 | 10–25% | Individual |
| WALSH, TIMOTHY, FARLEY Control | CFO since Nov 2025 | Less than 5% | Individual |
| GANDRUD, SOREN ALEXANDER, MAKRIYANNIS Control Indirect owner via JHC MANAGER GP LLC | MANAGING MEMBER since Apr 2025 | 50–75% | Individual |
Ownership & leadership changes · 1 filing with changes since Dec 5, 2025
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedGANDRUD, SOREN ALEXANDER, MAKRIYANNIS · title CIO, MANAGING PARTNER → CIO, LIMITED PARTNER
- ListedGANDRUD, SOREN ALEXANDER, MAKRIYANNIS · MANAGING MEMBER · 50–75% · indirect via JHC MANAGER GP LLC · control person
- ListedGANDRUD, SOREN ALEXANDER, MAKRIYANNIS · CIO, MANAGING PARTNER · 75% or more · control person
- ListedJHC MANAGER GP LLC · GENERAL PARTNER · Less than 5% · control person
- ListedMEEKINS, CHRISTOPHER, MARTIN · CCO, COO. GC, PARTNER · 10–25% · control person
- ListedWALSH, TIMOTHY, FARLEY · CFO · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- PHARVARIS N V$7.9M +33.6%
- ACLARIS THERAPEUTICS INC$3.9M +41.5%
- DIANTHUS THERAPEUTICS INC$1.5M +26.6%
- PHATHOM PHARMACEUTICALS INC$268.7K +15.3%
Top Trims
- BIOMARIN PHARMACEUTICAL INC-$11.6M -14.2%
- BICARA THERAPEUTICS INC-$6.7M -25.3%
- RELMADA THERAPEUTICS INC-$5.5M -21.9%
- OLEMA PHARMACEUTICALS INC-$5.4M -75.2%
- IMMUNOCORE HLDGS PLC-$4.6M -28.5%
New Positions
- BIOCRYST PHARMACEUTICALS INC$59.0M
- TRAVERE THERAPEUTICS INC$56.5M
- INDIVIOR PHARMACEUTICALS INC$54.7M
- CELCUITY INC$30.4M
- IONIS PHARMACEUTICALS INC$26.8M
Exited Positions
- GILEAD SCIENCES INC$43.3M
- ARCUTIS BIOTHERAPEUTICS INC$28.6M
- MADRIGAL PHARMACEUTICALS INC$28.2M
- XENON PHARMACEUTICALS INC$22.2M
- ANI PHARMACEUTICALS INC$19.4M
Jones Hill Capital LP Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $70.3M | 11.93% | 1,171,859 | SH |
| 2 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $59.0M | 10.01% | 7,083,300 | SH |
| 3 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $56.5M | 9.59% | 959,634 | SH |
| 4 | INDIVIOR PHARMACEUTICALS INC | SUPN | 45579U109 | $54.7M | 9.29% | 1,526,685 | SH |
| 5 | PHARVARIS N V | PHVS | N69605108 | $31.3M | 5.32% | 987,637 | SH |
| 6 | CELCUITY INC | CELC | 15102K100 | $30.4M | 5.17% | 382,901 | SH |
| 7 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $26.8M | 4.55% | 599,826 | SH |
| 8 | SUPERNUS PHARMACEUTICALS | SUPN | 868459108 | $25.9M | 4.40% | 601,685 | SH |
| 9 | NUVATION BIO INC | NUVB | 67080N101 | $25.1M | 4.26% | 4,486,986 | SH |
| 10 | VERA THERAPEUTICS INC | VERA | 92337R101 | $21.1M | 3.57% | 652,218 | SH |
| 11 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $20.7M | 3.52% | 1,447,156 | SH |
| 12 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $19.8M | 3.36% | 1,064,233 | SH |
| 13 | RELMADA THERAPEUTICS INC | RLMD | 75955J402 | $19.7M | 3.35% | 5,237,628 | SH |
| 14 | ABIVAX SA | ABVX | 00370M103 | $14.1M | 2.40% | 142,558 | SH |
| 15 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $13.2M | 2.24% | 2,504,651 | SH |
| 16 | INSMED INC | INSM | 457669307 | $12.2M | 2.06% | 106,528 | SH |
| 17 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $11.8M | 2.01% | 83,426 | SH |
| 18 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $11.6M | 1.98% | 384,278 | SH |
| 19 | ERASCA INC | ERAS | 29479A108 | $8.9M | 1.52% | 610,118 | SH |
| 20 | CAPRICOR THERAPEUTICS INC | CAPR | 14070B309 | $8.5M | 1.43% | 892,532 | SH |
| 21 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $7.0M | 1.20% | 80,017 | SH |
| 22 | NEUROGENE INC | NGNE | 64135M105 | $6.1M | 1.03% | 217,700 | SH |
| 23 | CORBUS PHARMACEUTICALS HLDGS | CRBP | 21833P301 | $6.0M | 1.03% | 886,428 | SH |
| 24 | TONIX PHARMACEUTICALS HLDG C | TNXP | 890260839 | $5.5M | 0.93% | 563,739 | SH |
| 25 | SAGIMET BIOSCIENCES INC | SGMT | 786700104 | $5.0M | 0.84% | 502,587 | SH |
| 26 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $4.8M | 0.82% | 300,900 | SH |
| 27 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $3.6M | 0.61% | 126,744 | SH |
| 28 | ATTOVIA THERAPEUTICS INC | ATTO | 04987L102 | $3.1M | 0.53% | 182,295 | SH |
| 29 | PHATHOM PHARMACEUTICALS INC | PHAT | 71722W107 | $2.0M | 0.34% | 276,830 | SH |
| 30 | LEXEO THERAPEUTICS INC | LXEO | 52886X107 | $2.0M | 0.34% | 593,737 | SH |
| 31 | OLEMA PHARMACEUTICALS INC | OLMA | 68062P106 | $1.8M | 0.30% | 206,397 | SH |
| 32 | TENAX THERAPEUTICS INC | TENX | 88032L605 | $230.9K | 0.04% | 122,169 | SH |
| 33 | ALVOTECH | ALVO | L01800108 | $154.9K | 0.03% | 26,700 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-13 | $589.2M | 33 | 0002102314-26-000006 |
| 2026-06-30 | 2026-08-13 | $470.4M | 29 | 0002102314-26-000005 |
| 2026-03-31 | 2026-05-14 | $466.5M | 26 | 0002102314-26-000003 |
EIGHTH FLOOR SOUTH
NEW YORK, NY 10013